- Home
- EMD vs XNCR Comparison
EMD vs XNCR Comparison
Compare EMD & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMD
- XNCR
- Stock Information
- Founded
- EMD 2003
- XNCR 1997
- Country
- EMD United States
- XNCR United States
- Employees
- EMD N/A
- XNCR N/A
- Industry
- EMD Finance/Investors Services
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- EMD Finance
- XNCR Health Care
- Exchange
- EMD Nasdaq
- XNCR Nasdaq
- Market Cap
- EMD 527.7M
- XNCR 579.3M
- IPO Year
- EMD N/A
- XNCR 2013
- Fundamental
- Price
- EMD $9.90
- XNCR $8.54
- Analyst Decision
- EMD
- XNCR Buy
- Analyst Count
- EMD 0
- XNCR 7
- Target Price
- EMD N/A
- XNCR $27.50
- AVG Volume (30 Days)
- EMD 248.5K
- XNCR 855.3K
- Earning Date
- EMD 01-01-0001
- XNCR 08-04-2025
- Dividend Yield
- EMD 10.25%
- XNCR N/A
- EPS Growth
- EMD N/A
- XNCR N/A
- EPS
- EMD N/A
- XNCR N/A
- Revenue
- EMD N/A
- XNCR $127,228,000.00
- Revenue This Year
- EMD N/A
- XNCR N/A
- Revenue Next Year
- EMD N/A
- XNCR $28.84
- P/E Ratio
- EMD N/A
- XNCR N/A
- Revenue Growth
- EMD N/A
- XNCR N/A
- 52 Week Low
- EMD $7.85
- XNCR $7.16
- 52 Week High
- EMD $9.55
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- EMD 66.75
- XNCR 44.94
- Support Level
- EMD $9.75
- XNCR $8.05
- Resistance Level
- EMD $9.85
- XNCR $10.20
- Average True Range (ATR)
- EMD 0.08
- XNCR 0.57
- MACD
- EMD 0.00
- XNCR -0.01
- Stochastic Oscillator
- EMD 91.18
- XNCR 31.40
About EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management investment company. Its primary investment objective is to seek high current income and the secondary objective is to seek capital appreciation.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.